Gas in Liquid Advanced
Stability System

Hillhurst’s proprietary GLASSTM platform enables novel uses of therapeutic gases that, up until now, have been limited by inhaled delivery. We’ve developed a unique pipeline of novel liquid therapeutic candidates intended to treat patients with sickle cell disease, Parkinson’s disease, and acute pain.


Commitment to Patients

We are committed to realizing the full medical potential of therapeutic gases for patients in need. Driven by a sense of urgency to treat debilitating diseases with limited treatment options, Hillhurst is enhancing the way therapeutic gases are delivered, unlocking new applications through the development of novel liquid medicines.
Recent News
Hillhurst Biopharmaceuticals Receives Study May Proceed Letter From US FDA to Initiate Phase 1 Clinical Trial of HBI-002
SAN DIEGO, CA (April 23, 2021) Hillhurst Biopharmaceuticals, Inc. ("Hillhurst"), a clinical-stage biopharmaceutical company focused on developing oral therapies ...
Hillhurst Biopharmaceuticals Receives Funding For Development Of HBI-002 For Treatment of Ulcerative Colitis
SAN DIEGO, CA (March 25, 2021) Hillhurst Biopharmaceuticals, Inc., a biopharmaceutical company focused on developing therapies enabling the chronic ...